You are here: Home » Markets » News
'We have seen a drop in retail participation in the cash segment'
Business Standard

Dr Reddy's Q4 PAT falls 76% YoY on impairment costs; misses estimates

The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.

Topics
Dr Reddy's | Dr Reddys Laboratories | Q4 Results

Harshita Singh  |  New Delhi 



pharma

Dr Reddy's Laboratories, on Thursday, posted a 76 per cent year-on-year (YoY) decline in consolidated net profit at Rs 88 crores for the fourth quarter of financial year (Q4FY22), missing analyst estimates. This was due to impairment charges of Rs 751.5 crores during the quarter.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Thu, May 19 2022. 13:48 IST

RECOMMENDED FOR YOU

.